Vital

When the medication isn't working

Tirzepatide Medication Level Chart: Half-Life, Steady State

A tirzepatide medication level chart and a semaglutide level chart built from label half-lives, with tables for one dose, the build-up to steady state, the weekly rise and fall, and a missed dose.

Last reviewed

The Vital angle

On iPhone, each logged dose in Vital has a Still in your system card with the percent of that dose left, the half-life used, and when it is mostly gone, counted as five half-lives. Blends get one row per part, and compounds without human data carry a caveat. The card follows one dose at a time, not a steady-state curve.

Tirzepatide medication level chart: the short answer

A tirzepatide medication level chart estimates how much drug is in your body over time, from its half-life. The Zepbound label lists an elimination half-life of about 5 to 6 days, so about half of one dose is left after 5 to 6 days and about 3% is left after 25 to 30 days. With the same weekly dose, the level builds for about 4 weeks, then stays in a steady weekly rise and fall. The label says steady state comes after 4 weeks of once-weekly use.

Semaglutide follows the same pattern with a longer half-life. The Ozempic and Wegovy labels list about 1 week. The Ozempic label says steady state comes after 4 to 5 weeks, and that semaglutide stays in the circulation for about 5 weeks after the last dose. The Wegovy label says about 5 to 7 weeks after the last dose of its higher strengths.

The charts here use a simple model and label values. They show the shape of the curve, not your own blood level. They are not a guide to dosing. Your prescriber sets the dose and the schedule.

How half-life works

The half-life is the time it takes for the amount of a drug in the body to fall by half. After one half-life, 50% of a dose is left. After two, 25%. After five half-lives, about 3% is left, which is the usual shorthand for "mostly gone." The fall never reaches exactly zero, so any "cleared" date is a convention.

Two other label values shape the curve:

  • Time to peak. For tirzepatide, the label lists a median of 24 hours after the injection, with a range of 8 to 72 hours. For Wegovy, the peak comes 1 to 3 days after the dose.
  • Injection site. Both labels report similar exposure from the abdomen, thigh, and upper arm.

One dose over time

This table shows the part of one dose left after each interval, from the half-life alone. It ignores absorption, so the first day or two look lower in real life while the drug is still being absorbed.

Days after the dose Tirzepatide, 5-day half-life Tirzepatide, 6-day half-life Semaglutide, 7-day half-life
0 100% 100% 100%
7 38% 45% 50%
14 14% 20% 25%
21 5% 9% 13%
28 2% 4% 6%
35 1% 2% 3%

This is why the drug effect, and side effects, can last for weeks after a last dose. The FDA notes that semaglutide's half-life of about one week means an overdose can need a long period of observation.

Build-up to steady state

When you inject the same dose each week, part of each dose is still there when the next one goes in. The level climbs each week until the amount you add equals the amount the body clears in a week. That balance is steady state.

The table shows the lowest level of each week, just before the next shot, as a share of the steady-state low. Same dose every week, simple model.

Week Tirzepatide, 5-day half-life Semaglutide, 7-day half-life
1 62% 50%
2 86% 75%
3 95% 88%
4 98% 94%
5 99% 97%

The rule of thumb is that steady state takes 4 to 5 half-lives. For tirzepatide, that matches the label's 4 weeks. For semaglutide, it matches the Ozempic label's 4 to 5 weeks.

At steady state, the level is higher than after one dose. With weekly shots, the model gives about 1.6 times the single-dose level for a 5-day half-life, about 1.8 times for a 6-day half-life, and about 2 times for a 7-day half-life.

The Zepbound label lists a 2.5 mg starting dose for 4 weeks, and increases in 2.5 mg steps after at least 4 weeks on the current dose. Each step starts a new climb to a new steady state. Your prescriber decides when and whether to change the dose. For effects after a step up, see side effects after a dose increase.

The weekly rise and fall at steady state

Even at steady state, the level is not flat. It rises after each shot and falls until the next one. In the simple model, the end-of-week low is:

Half-life Low as a share of the high
Tirzepatide, 5 days About 38%
Tirzepatide, 6 days About 45%
Semaglutide, 7 days About 50%

Real curves are smoother than this, because the drug absorbs over 1 to 3 days. Some people notice appetite or side effects change across the week. That pattern is worth a note in your log, so you can show your prescriber. Do not move your shot day to change it without asking them.

To draw the curve with your own dates, use the free GLP-1 level chart tool. It plots an estimated level over time from the half-life, and it is not a lab test.

What a missed dose does to the level

If you skip one weekly dose at steady state, the level keeps falling for another week. In the simple model, the low at the end of the second week is about 38% of your usual weekly low for tirzepatide with a 5-day half-life, and about 50% for semaglutide. It then takes a few weeks of regular shots to climb back.

The labels give exact rules for a missed dose:

Medication The label lists
Zepbound Take it within 4 days (96 hours) of the missed dose. If more than 4 days passed, skip it and take the next dose on the usual day. Keep at least 3 days (72 hours) between two doses.
Wegovy injection If the next dose is more than 2 days away, take it as soon as possible. If it is less than 2 days away, skip it. If 2 or more doses in a row are missed, the label says to restart the dose escalation at a lower dose.
Ozempic Take it within 5 days of the missed dose. If more than 5 days passed, skip it. Keep at least 2 days (48 hours) between two doses.

After a longer break, ask your prescriber how to restart. See missed GLP-1 dose and switching semaglutide to tirzepatide.

How Vital shows what is still in your system

On iPhone, when you open a logged dose in Vital, a "Still in your system" card shows how much of that dose is left now, as a percent, with a bar that gets shorter over time. It shows the half-life it used, from Vital's peptide directory, and when the dose is "mostly gone," which it counts as five half-lives. For a blend, each part gets its own row. For a compound with no published human data, it says so, and a compound with no published half-life shows "Not established."

The card follows one dose at a time. It does not add doses together into a steady-state curve, so use the GLP-1 level chart tool for that view. Vital also keeps your dose history and weight in one place, which helps when you compare changes in appetite or weight with your dose dates. See the GLP-1 weight loss tracker guide and the free weight loss calculator.

Limits of any medication level chart

  • It is a model. Real levels vary with body weight, kidney function, and other factors. The label half-life is a population average.
  • It is not a lab test. No home chart shows your actual blood level.
  • Compounded and research products vary. A compounded vial has the same drug but a different label. For investigational compounds such as retatrutide, there is no approved label, so any half-life comes from trial reports. See retatrutide dosage chart and how long peptides stay in your system.
  • Level is not effect. A higher level does not mean more weight loss in a straight line.

Get emergency care for severe stomach pain that does not stop, which can be a sign of pancreatitis, vomiting that stops you from keeping fluids down, swelling of the face or throat, or trouble breathing. Because these drugs stay in the body for weeks, effects can continue after a missed or stopped dose.


Ozempic® and Wegovy® are trademarks of Novo Nordisk A/S. Zepbound® is a trademark of Eli Lilly and Company. Vital is independent and not affiliated with these companies.

Free toolGLP-1 medication level chart

Things to watch

Practical flags drawn from prescribing information and clinical guidance. Vital surfaces these in the dose log to help you spot them early.

  • Reading a model as a blood test

    A level chart uses the label half-life, a population average. It shows the shape of the curve, not your own blood level.

  • Judging a dose before steady state

    The Zepbound label says steady state comes after 4 weeks of weekly use, and the Ozempic label says 4 to 5 weeks for semaglutide. Early weeks run lower than later weeks at the same dose.

  • Doubling up after a missed dose

    The labels set minimum gaps between doses: 72 hours for Zepbound and 48 hours for Ozempic. Follow the label rule or ask your prescriber.

  • Restarting at the old dose after a long break

    The Wegovy label says to restart the dose escalation at a lower dose after 2 or more missed doses in a row. Ask your prescriber how to restart.

  • Half-lives for research compounds

    Investigational compounds such as retatrutide have no approved label. Any half-life comes from trial reports and can change as data grows.

Frequently asked questions

  • The Zepbound label lists a half-life of about 5 to 6 days. About 3% of one dose is left after five half-lives, which is about 25 to 30 days. Effects can last part of that time.

  • The Zepbound label says steady-state levels come after 4 weeks of once-weekly use. Each dose step starts a new climb to a new steady state.

  • With a half-life of about 1 week, about half of one dose is left after 7 days and about a quarter after 14 days. The Ozempic label says semaglutide stays in the circulation for about 5 weeks after the last dose.

  • The level keeps falling for another week, to roughly 38 to 50% of the usual weekly low in a simple model. Follow the missed-dose rule on your label or ask your prescriber.

  • Even at steady state, the level rises after each shot and falls until the next. In a simple model, the weekly low is about 38 to 50% of the high. Note the pattern and tell your prescriber.

  • It is an estimate from the label half-life, which is an average. It shows the general shape of the curve, not your blood level. Only a lab test measures an actual level.

Sources

  1. Zepbound (tirzepatide) prescribing information · Eli Lilly and Company
  2. Wegovy (semaglutide) prescribing information · Novo Nordisk A/S
  3. Ozempic (semaglutide) prescribing information · Novo Nordisk A/S
  4. FDA alerts health care providers, compounders and patients of dosing errors associated with compounded injectable semaglutide products · U.S. Food and Drug Administration

This page summarizes publicly available information from the sources listed above and is for educational use only. It is not medical advice. Consult a qualified healthcare professional for personal dosing guidance.

Track every shot, every change

Vital logs every GLP-1 injection and peptide dose, then surfaces patterns your scale can't show. Free on iOS and Android.